- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Corporate and Securities Litigation
- E-Discovery
- Global Construction and Infrastructure Disputes
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Geneviève Michaux
Insights 15 results
Client Alert
December 22, 2025
EUROPE - Major Regulatory Developments in Pharmaceuticals, Biotechnology, and Medical Devices
Article · Source: Financier Worldwide
October 16, 2025
Update to the European rules on advertising medicinal products
Client Alert
July 11, 2025
FDA Publishes More Than 200 Complete Response Letters (CRLs) With More to Come
Client Alert
June 24, 2025
EUROPE – European Commission Excludes Chinese Medical Device Manufacturers from EU Public Procurement Contracts
Client Alert
Client Alert
March 19, 2025
France Adopts a Law Banning PFAS in Cosmetics, Textiles, and Waxing Products
Client Alert
Article · Source: The Guide to Life Sciences - Third Edition
August 14, 2024
European Union: Commission zeroes in on innovation in merger control and pay-for-delay cases
Article · Source: Law360
August 6, 2024
A Primer On EU's Updated Human Substance Regulations
Article · Source: Law360
October 23, 2023
How Int'l Regulatory Collabs Can Expedite Pharma Approvals
Article · Source: The Guide to Life Sciences - Second Edition
October 20, 2023
European Union: Commission Intensifies Merger Review Focus on Pipeline Products and Pay-for-Delay Cases in the Spotlight
Article · Source: Bioprocess Online
September 1, 2023
How To Navigate The EU's New Interim PSA Program